TITLE:
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

CONDITION:
Leukemia

INTERVENTION:
Thalidomide

SUMMARY:

      The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients
      with leukemia.
    

DETAILED DESCRIPTION:

      Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be
      increased gradually and modified according to side-effects. The drug will be given daily up
      to the time of complete remission then as long as it is beneficial.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Diagnosis of refractory or relapsed leukemia: acute leukemia, CML, CLLm and MDS.

          -  Signed informed consent, including patient agreeing to use safe contraceptive methods
             during the treatment and for at least 4 months after the treatment is completed

          -  Serum creatinine < or = 2.5mg/dL

          -  Serum bilirubin< or = 2.5mg/dL

          -  Negative pregnancy test

          -  Age 18 years or older

          -  Performance status < or = 3

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Concurrent treatment with cytotoxic chemotherapy, or radiation

          -  History of seizures, neurotoxicity, or active CNS disease

          -  Serious infections not controlled by antibiotics
      
